A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)
Uloženo v:
| Název: | A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG) |
|---|---|
| Autoři: | Degirmencioglu S, Tanriverdi O, Menekse S, Dogan M, Hacıoglu B, Oktay E, Erdem D, Arpaci E, Uluc BO, Turhal S, Yilmaz M, Pilanci KN, Sakin A, Araz M, Cokmert S, Ozdemir O, Sen E, Nayir E |
| Zdroj: | Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 24(1) |
| Informace o vydavateli: | Zerbinis Publications, 2019. |
| Rok vydání: | 2019 |
| Témata: | Male, Lung Neoplasms, intestine perforation, Turkey, retrospective study, diarrhea, Pooled Analysis, Cetuximab, thrombocytopenia, medical record review, fluorouracil, 0302 clinical medicine, middle aged, Antineoplastic Combined Chemotherapy Protocols, genetics, malignant hypertension, cancer survival, disease free survival, Braf-Mutation, Aged, 80 and over, progression free survival, adult, Panitumumab, Liver Neoplasms, clinical trial, Prognosis, Folfox4, anemia, 3. Good health, Bevacizumab, Survival Rate, aged, survival rate, liver tumor, folinic acid, bevacizumab, blood transfusion, cancer prognosis, Article, deep vein thrombosis, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, colorectal carcinoma, turkey (bird), cancer combination chemotherapy, neutropenia, Humans, human, Aged, Retrospective Studies, cancer immunotherapy, protein p21, oxaliplatin, nail disease, dehydration, KRAS protein, Adult, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Bevacizumab/administration & dosage, Cetuximab/administration & dosage, Colorectal Neoplasms/*drug therapy/genetics/pathology, Female, Follow-Up Studies, Liver Neoplasms/*drug therapy/genetics/secondary, Lung Neoplasms/*drug therapy/genetics/secondary, Middle Aged, Mutation, Panitumumab/administration & dosage, Proto-Oncogene Proteins p21(ras)/*genetics, Colorectal cancer, major clinical study, infection, drug efficacy, multicenter study, nausea and vomiting, neuropathy, observational study, prognosis, proteinuria, mutation, colorectal tumor, drug safety, KRAS protein, human, very elderly, Leucovorin, rash, lung tumor, cetuximab, Plus Irinotecan, irinotecan, antineoplastic agent, metastatic colorectal cancer, female, Metastatic, mucosa inflammation, Fluorouracil, secondary, Colorectal Neoplasms, lung embolism, ileus, epistaxis, overall survival, tumor localization, heart arrhythmia, male, acute kidney failure, KRAS, Chemotherapy, follow up, controlled study, Colorectal Cancer, constipation, hand foot syndrome, K ras protein, febrile neutropenia, Kras, pathology, panitumumab |
| Popis: | To compare the efficacy and adverse effect profiles of the first-line treatment of patients with KRAS wild type metastatic colorectal cancer (CRC) in Turkey who were treated based on regimens including bevacizumab, cetuximab and panitumumab.This retrospective multicenter observational study involved a total of 238 patients who received chemotherapy in combination with either bevacizumab or cetuximab or panitumumab as first-line therapy for KRAS wild-type metastatic colorectal cancer. Patients with full medical records having pathological diagnosis of CRC adenocarcinoma were included in the study. The demographic, laboratory, histopathological and clinical characteristics of the patients were determined, and three groups were compared based on the study variables.The mean age of the entire sample (n=238) was 58±11 years, 64% of which were male. The most frequent tumor localization was the rectum (37%) and G2 was the most common tumor grade (59.7%). About 63% of the patients had metastatic disease at diagnosis, with the most common site of metastasis being lung (14.7%) and liver (52.5%). Overall survival (OS) was 63.9%, while 1-, 3- and 5-year survival rates were 91.7, 56.6 and 36.9%, respectively. The expected mean survival was 49.1 months (95% CI, 42.9-55.3). The 1-, 3- and 5-year progression-free survival (PFS) rates following first-line treatment were 65.3, 26.1 and 5.6%, respectively, while disease free survival (DFS) in patients without metastasis at diagnosis was 68.5%. An analysis carried out disregarding which treatment the patients received (FOLFOX or FOLFIRI) revealed that a panitumumab-containing combination resulted in poorer prognosis compared to bevacizumab or cetuximab-containing combination (p |
| Druh dokumentu: | Article |
| Jazyk: | English |
| ISSN: | 2241-6293 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/30941962 https://avesis.yyu.edu.tr/publication/details/2691f661-6a65-4364-a1ee-aa7479a4ba21/oai https://avesis.yyu.edu.tr/publication/details/6e7976cd-0cc7-4df7-9db1-60baf793a782/oai https://hdl.handle.net/11499/30529 https://hdl.handle.net/20.500.14551/19050 |
| Přístupové číslo: | edsair.pmid.dedup....f20bccbc3a47d9e917a5412f4b170e35 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | To compare the efficacy and adverse effect profiles of the first-line treatment of patients with KRAS wild type metastatic colorectal cancer (CRC) in Turkey who were treated based on regimens including bevacizumab, cetuximab and panitumumab.This retrospective multicenter observational study involved a total of 238 patients who received chemotherapy in combination with either bevacizumab or cetuximab or panitumumab as first-line therapy for KRAS wild-type metastatic colorectal cancer. Patients with full medical records having pathological diagnosis of CRC adenocarcinoma were included in the study. The demographic, laboratory, histopathological and clinical characteristics of the patients were determined, and three groups were compared based on the study variables.The mean age of the entire sample (n=238) was 58±11 years, 64% of which were male. The most frequent tumor localization was the rectum (37%) and G2 was the most common tumor grade (59.7%). About 63% of the patients had metastatic disease at diagnosis, with the most common site of metastasis being lung (14.7%) and liver (52.5%). Overall survival (OS) was 63.9%, while 1-, 3- and 5-year survival rates were 91.7, 56.6 and 36.9%, respectively. The expected mean survival was 49.1 months (95% CI, 42.9-55.3). The 1-, 3- and 5-year progression-free survival (PFS) rates following first-line treatment were 65.3, 26.1 and 5.6%, respectively, while disease free survival (DFS) in patients without metastasis at diagnosis was 68.5%. An analysis carried out disregarding which treatment the patients received (FOLFOX or FOLFIRI) revealed that a panitumumab-containing combination resulted in poorer prognosis compared to bevacizumab or cetuximab-containing combination (p |
|---|---|
| ISSN: | 22416293 |